Long-term treatment with antiviral nucleoside analogue drugs, such as AZT, can give rise to
delayed and at times severe mitochondrial toxicity. Although these toxic effects are manifest
in many tissues, a common disease mechanism can explain the diverse clinical events. A
better understanding of these disorders will shed light on genetic mitochondrial diseases
and lead to the design of safer and more effective antiviral drugs.